Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-HER2 CAR monocytes CT-0525

A preparation of autologous monocytes genetically modified to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-HER2 CAR monocytes CT-0525 specifically recognize and bind to HER2-expressing tumor cells, and expose the immune system to the HER2 antigen. This may elicit a cytotoxic T-lymphocyte (CTL) response against HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.
Synonym:autologous anti-HER2 CAR-mono CT-0525
autologous anti-HER2 CAR-monocytes CT-0525
Code name:CT 0525
CT-0525
CT0525
Search NCI's Drug Dictionary